Vimarsana
Biggest News Aggregation in the World

Page 4 - Mayo Score News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mayo Score. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mayo Score Today - Breaking & Trending Today

Guselkumab and Golimumab: Better Together for Ulcerative Colitis - Vimarsana News

Guselkumab and Golimumab: Better Together for Ulcerative Colitis

People with moderate-to-severe ulcerative colitis benefit from a combination of these monoclonal antibodies, compared with induction with either agent alone, according to a new phase 2a study.

New TREMFYA® (guselkumab) Data Show an Overall Clinical Response Rate of Approximately 80 Percent in a Phase 2b Induction Study of Adults with Moderately to Severely Active Ulcerative Colitis - Vimarsana News

New TREMFYA® (guselkumab) Data Show an Overall Clinical Response Rate of Approximately 80 Percent in a Phase 2b Induction Study of Adults with Moderately to Severely Active Ulcerative Colitis

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2b QUASAR Induction Study 1 in adults with...

ABIVAX: First US Patient Enrolled in Global Phase 3 Program with Obefazimod in Ulcerative Colitis - Vimarsana News

ABIVAX: First US Patient Enrolled in Global Phase 3 Program with Obefazimod in Ulcerative Colitis

First patient enrolled into the global phase 3 program with obefazimod ("ABTECT-Program") for the treatment of moderate to severe ulcerative colitis (UC) in the US1,200 UC patients across 36 countries

Johnson & Johnson : Results of Novel Clinical Study of Guselkumab and Golimumab Combination Therapy Show Adults with Moderately to Severely Active Ulcerative Colitis Maintained Higher Rates of Clinical, Histologic, and Endoscopic Remission at Week 38 - Vimarsana News

Johnson & Johnson : Results of Novel Clinical Study of Guselkumab and Golimumab Combination Therapy Show Adults with Moderately to Severely Active Ulcerative Colitis Maintained Higher Rates of Clinical, Histologic, and Endoscopic Remission at Week 38

The rate of clinical remission was 47.9 percent in patients who received combination induction therapy with guselkumab and golimumab compared with either treatment alone at 38 weeks1 ... | October 10, 2022

The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort study | BMC Medicine - Vimarsana News

The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort study | BMC Medicine

The durability of vaccine-induced humoral immunity against SARS-CoV-2 in patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive therapy is not known. The aim of this study was to compare the persistence of anti-Spike antibodies following two-dose SARS-CoV-2 vaccination between IMID patients and healthy controls and to identify factors associated with antibody decline. IMID patients on immunosuppressive medication enrolled in the prospective observational Nor-vaC study were included. Participants received two-dose SARS-CoV-2 vaccination. Serum collected at two time poi...